<DOC>
	<DOCNO>NCT00004399</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine effectiveness nimodipine versus magnesium sulfate prevention eclamptic seizure patient severe preeclampsia .</brief_summary>
	<brief_title>Randomized Study Nimodipine Versus Magnesium Sulfate Prevention Eclamptic Seizures Patients With Severe Preeclampsia</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomized , international , multicenter study . Patients randomize receive either nimodipine magnesium sulfate . Arm I : Patients receive nimodipine mouth every 4 hour . Treatment continue 24 hour post-partum . Arm II : Patients receive load dose magnesium sulfate IV 20 minute , follow continuous infusion magnesium sulfate . Treatment continue 24 hour post-partum .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Eclampsia</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<mesh_term>Nimodipine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically diagnose severe preeclampsia risk eclamptic convulsion follow criterion : Blood pressure great 160/110 mmHg OR Mean arterial pressure 126 mmHg Proteinuria great 5 g/24 hr Epigastric pain OR Right upper quadrant pain AST/ALT great 70 U/L Severe headache and/or scotoma Thrombocytopenia evidence : Platelet count le 100,000/mm3 Disseminated intravascular coagulation Microangiopathic hemolytic anemia Oliguria ( less 400 mL/day 30 mL/hr ) Pulmonary edema Prior/Concurrent Therapy No prior/concurrent magnesium sulfate dihydropyridine agents No concurrent antiseizure medication Patient Characteristics Age : Not specify Performance status : Not specify Hematopoietic : See Disease Characteristics Hepatic : See Disease Characteristics Renal : No severe renal failure See Disease Characteristics Cardiovascular : No history angina myocardial infarction No cardiac dysfunction No history sign congestive cardiac failure No arrhythmia ventricular rate le 60 bpm See Disease Characteristics Pulmonary : See Disease Characteristics Other : No severe mental physical disorder may affect therapy Not allergic drug chemical structure similar nimodipine magnesium sulfate No evidence fetal distress fetal anomaly</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>hypertensive disorder</keyword>
	<keyword>pre-eclampsia</keyword>
	<keyword>rare disease</keyword>
</DOC>